

Vasomedical, Inc.

180 Linden Avenue
Westbury, New York 11590
Tel: (516) 997-4600 Fax: (516) 997-2299

NEWS RELEASE

Contact:

Dr. John C.K. Hui, President & CEO
(516) 997-4600
Tricia Efstathiou, CFO
(516) 997-4600

Investor Relations:

(516) 997-4600 ext. 790
customerservice@vasomedical.com

Additional Beneficial Effects of Vasomedical EEC[®] Therapy Reported in Five Presentations During the 57th Annual Scientific Session of the American College of Cardiology

WESTBURY, N.Y. (April 2, 2008) – Vasomedical, Inc. (“Vasomedical”) (OTC: VASO.OB), a leader in the noninvasive treatment and management of cardiovascular diseases, today announced that five presentations on the beneficial effects and the mechanisms of action of EEC[®] external counterpulsation therapy have been presented at the 57th Scientific Session of the American College of Cardiology in Chicago.

There were two presentations related to the mechanisms of action of EEC[®] therapy. Barry A. Boilson, MD, Gregory Barsness, MD and co-researchers from the Mayo Clinic in Rochester, MN presented “Circulating Progenitor Cells and Erythropoietin Levels in Patients Undergoing Enhanced External Counterpulsation.” The researchers demonstrated a significant increase in endothelial progenitor cells released from bone marrow in patients undergoing EEC[®] therapy. The authors concluded that homing of these cells to the coronary vasculature may effect improvements in vascular function and clinical symptomatic improvements.

“While the observed symptomatic improvement associated with EEC[®] therapy has been established now for many years, the exact mechanism or mechanisms of effect remain somewhat elusive. Recent work by our group and others suggest an improvement in endothelial function and perhaps overall vascular health as an important pathway for this observed clinical benefit. Mobilization of progenitor cells and induction of vasoactive molecules as a means to endothelial function improvement is an attractive and promising area for further investigation,” stated Dr. Barsness.

341(nha) S:\c\he6538(s)43478 (by)lc1869(c)3.9567(on)l71.839B04D(G)u304(60341m)E7r B.C.6087(mh)CL97d/R9(676873)95

Dr. Lawson also presented a study conducted by Dr. Himanshu Padh and Dr. Subramanian Ramasamy at Samarpan Heart Hospital and Research Center and the People's College of Medical Sciences in Jamnagar, India entitled "Effect of Enhanced External Counterpulsation on Ejection Fraction in Patients with Ischemic Heart Disease." The authors concluded that EECP® therapy significantly increased ejection fraction and stroke volume. The underlying mechanisms may include improvement in left ventricular contractility due to improved myocardial perfusion, and/or afterload reduction secondary to the normalization of endovascular tone and function.

According to Dr. William Lawson, "The ACC presentations included exciting new developments in EECP® therapy. Dr. Boilson and colleagues from the Mayo Clinic demonstrated that EECP® treatment was associated with a significant increase in endothelial progenitor cells, potentially an important underlying mechanism for improving endovascular repair, time and function. Dr. McHugh and colleagues from Lutheran Medical Center demonstrated that EECP® therapy improves functional tolerance, regional and global function and decreases mitral regurgitation in end stage coronary artery disease patients. These findings were supported by Drs. Padh's and Ramasamy's study from India, showing EECP® treatment in advanced coronary artery disease improved ejection fraction and stroke volume potentially through effects on afterload reduction or improved myocardial perfusion. Finally a study from the IEPR, a registry of 8,000 patients, demonstrated for the first time an association of EECP® treatment completion with improved one-year survival in end stage coronary artery disease patients. All in all it was an exciting program featuring promising new developments in EECP® therapy"

"EECP® therapy is an evidence-based therapy; the benefits, safety and effectiveness of Vasomedical EECP® therapy have been well documented in over one hundred scientific and clinical journal articles published in peer-reviewed medical journals. These presentations further reinforce improved clinical outcomes in the treatment of patients suffering from angina pectoris and heart failure," commented Dr. John Hui, president and CEO of Vasomedical, Inc.

Further information about these studies is available at the American College of Cardiology website, www.acc.org.

About Vasomedical, Inc. and EECP® Therapy

Vasomedical, Inc. develops, manufactures and markets EECP® therapy systems to deliver its proprietary form of enhanced external counterpulsation therapy. EECP® therapy is a noninvasive, outpatient therapy used in the treatment of ischemic cardiovascular diseases, currently used to manage chronic stable angina and heart failure. The therapy increases blood flow and oxygen supply to the heart muscle and other organs and decreases the heart's workload and need for oxygen. Function of the endothelium, the inner lining of blood vessels throughout the body, is also improved, lessening resistance to blood flow. These actions reduce or eliminate symptoms of angina and heart failure, and improve exercise performance and quality of life for thousands of people worldwide. For more information visit www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipated," "believes," "could," "estimates," "expects," "may," "offers," "plans," "potential," and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

###